Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2015-07-31 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 95% confidence The document is an official announcement of Ipsen's 2015 half-year financial results. It contains key financial highlights, tables comparing H1 2015 to H1 2014, management commentary, and updated financial guidance. While it references the full interim financial report being available on the website, the document itself provides substantive financial data and analysis, qualifying it as an Earnings Release (ER) rather than a mere announcement of a report (RPA). H2 2015
2015-07-31 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (June 30, 2015). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory disclosure regarding the capital structure, even though it is a monthly update rather than a specific transaction announcement. It is not a dividend notice (DIV), a major shareholding notification (MRQ), or a general regulatory filing (RNS), as it is highly specific to capital structure reporting.
2015-07-07 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled "Monthly information regarding the total number of voting rights and total number of shares of the Company" and references Article 223-16 of the AMF General Regulations. It provides a monthly update (June 30, 2015) on the total number of shares and voting rights. This specific type of mandatory monthly disclosure regarding share capital structure and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a regulatory disclosure concerning capital structure and ownership rights, but it is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or a general Share Issue (SHA). Given the specific nature of reporting voting rights monthly, and lacking a dedicated code, the most appropriate fallback category for a specific, recurring regulatory disclosure that doesn't fit elsewhere is Regulatory Filings (RNS).
2015-07-07 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité IPSEN contracté avec NATIXIS" (Semi-annual balance sheet of the IPSEN liquidity contract with NATIXIS). It details the holdings (shares and cash) in a liquidity account as of June 30, 2015, and compares them to the previous semi-annual balance from December 31, 2014. This type of regular update concerning share buyback programs or liquidity management contracts, which involves the company's own shares, fits best under 'Transaction in Own Shares' (POS) as it relates directly to the management of the company's stock outside of standard capital changes or dividends. It is a specific report on share transactions/holdings related to a liquidity agreement.
2015-07-03 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Capital/Financing Update Classification · 99% confidence The document text explicitly discusses a 'Half-year IPSEN liquidity contract statement' dated June 30, 2015, comparing it to a previous statement from December 31, 2014. This content relates to the management of company shares or financial instruments, specifically concerning liquidity provision. While it is a statement, it is not a standard comprehensive financial report (like 10-K or IR). It details the status of a specific financial arrangement (liquidity contract) involving shares and cash. This type of specific financial disclosure, often related to market operations or share management, fits best under the 'Transaction in Own Shares' (POS) category if it relates to share buybacks/issuance, or potentially a general 'Regulatory Filing' (RNS). Given the context of a 'liquidity contract statement' detailing share holdings and cash reserves related to that contract, it is a specific financial transaction disclosure. However, since the definitions do not perfectly capture a 'Liquidity Contract Statement,' I must choose the closest fit. POS covers 'Report of the company buying back or selling its own shares (share repurchase/issuance).' A liquidity contract is often set up to support the market price, which is related to share transactions. If this were a general announcement about a dividend or capital change, other codes would apply. Since it is a statement about the status of a contract managing share inventory, POS is the most relevant specific financial activity code. If it were purely informational without direct transaction reporting, RNS would be the fallback. Given the detailed figures of shares and Euros held under the contract, POS is the stronger classification.
2015-07-03 English
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 99% confidence The document is titled 'Ipsen provides an update on 2020 strategy and outlook at Investor Day' and details strategic plans, financial outlook targets (€1.8bn to €2bn sales by 2020), and outlines the schedule for an analyst meeting/webcast. This content is characteristic of an Investor Presentation (IP) where management presents forward-looking strategy and financial guidance to the investment community, distinct from a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses on historical period results. The mention of hosting an 'analyst meeting' and providing a 'comprehensive review of its 2020 strategy' strongly points to an Investor Presentation.
2015-07-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.